Caredx Inc (CDNA) Peer Comparison
$88.77
$2.89
(3.37%)
As on 03-Nov-2026 15:35EST
Market cap
$4,522 Mln
Revenue (TTM)
$497 Mln
P/E Ratio
42
P/B Ratio
9.8
Div. Yield
0 %
Edit
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
4,522 | 16,932 | 10,811 | 5,010 | 3,479 |
Revenue ($ Mln) |
497 | 2,497 | 102 | 1,156 | -- |
Net Profit ($ Mln) |
128.63 | 885.14 | -349.47 | -105.97 | -627.20 |
Net Margin (%) |
25.86 | 35.45 | -341.87 | -9.17 | -- |
RoE (%) |
32.94 | 46.96 | -22.16 | -- | -115.03 |
Price to Earnings |
42.02 | 20.78 | -- | -- | -- |
Price-To-Book |
9.83 | 9.23 | 6.49 | 1,743.27 | 5.82 |
Income Statement ($ Mln)
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
497.40 | 2,496.86 | 102.23 | 1,155.55 | 0.00 |
|
Cost of Revenue
|
144.39 | 93.32 | -74.16 | 87.91 | 0.09 |
|
Gross Profit
|
256.57 | 2,236.43 | 39.20 | 1,658.90 | -0.43 |
|
Operating Expenses
|
348.88 | 1,400.14 | 583.29 | 929.29 | 648.57 |
|
Operating Profit (EBIT)
|
4.13 | 1,003.39 | -404.89 | 138.35 | -648.57 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
124.22 | 1,065.84 | -349.70 | -85.09 | -627.20 |
|
Provision for Tax
|
-4.41 | 180.70 | 0.00 | 20.88 | 0.00 |
|
Profit after Tax (Net Income)
|
128.63 | 885.14 | -349.47 | -105.97 | -627.20 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
467.46 | 1,833.83 | 1,614.53 | -191.21 | 588.60 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
35.03 | 267.78 | 63.02 | 2,622.85 | 254.67 |
|
Current Liabilities
|
138.98 | 411.88 | 89.72 | 776.08 | 133.90 |
|
Total Liabilities
|
413.23 | 2,844.42 | 1,742.81 | 2,898.77 | 715.73 |
Assets ($ Mln)
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
320.16 | 1,191.87 | 768.68 | 669.93 | 4.17 |
|
Current Assets
|
321.30 | 1,321.62 | 998.59 | 2,537.78 | 973.00 |
|
Total Assets
|
413.23 | 2,844.42 | 1,742.81 | 2,898.77 | 715.73 |
|
Total Debt*
|
29.00 | 162.20 | 76.60 | 636.03 | 254.69 |
|
Net Current Assets
|
0.00 | 909.75 | 908.87 | 0.00 | 839.10 |
Cashflow ($ Mln)
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
42.03 | 884.27 | -232.89 | 711.20 | -278.69 |
|
Cash Flow from Investing Activities
|
2.16 | 350.44 | -521.06 | -861.98 | 341.39 |
|
Cash from Financing Activities
|
-93.39 | -969.59 | 990.71 | 331.09 | 76.44 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-5.80 | 32.82 | -24.09 | 35.24 | -47.30 |
|
ROE (%)
|
32.94 | 46.96 | -22.16 | -104.75 | -115.03 |
|
ROA (%)
|
17.22 | 28.91 | -23.06 | -2.29 | -66.85 |
|
EBIT Margin (%)
|
1.35 | 42.02 | -341.82 | 9.82 | -- |
|
Net Margin (%)
|
25.86 | 35.45 | -341.87 | -9.17 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
38.94 | 9.12 | 133.74 | -35.05 | -- |
|
EBIT Growth (%)
|
121.67 | 23.13 | -18.50 | -87.09 | -164.25 |
|
Net Profit Growth (%)
|
111.69 | 30.57 | -18.42 | -114.10 | -164.20 |
|
EPS Growth (%)
|
133.38 | 38.78 | -2.42 | -116.63 | -155.36 |
|
Book Value Growth (%)
|
46.83 | -7.57 | 48.81 | -28.11 | -21.46 |
Valuation Ratios
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-45.11 | 15.79 | -21.09 | 8.98 | -11.15 |
|
Price / Book Value
|
3.18 | 5.72 | 4.16 | -29.85 | 6.28 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-174.47 | 12.44 | -19.14 | 7.76 | -9.20 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.00 | 0.43 |
|
Short term debt to equity ratio
|
0.02 | 0.00 | 0.01 | -0.07 | 0.00 |
|
Current Ratio
|
2.31 | 3.21 | 11.13 | 3.27 | 7.27 |
|
Quick Ratio
|
2.25 | 3.14 | 11.13 | 3.13 | 7.27 |
|
Interest Coverage
|
-- | -- | -1,279.94 | 0.57 | -7,126.22 |
Operating Efficiency Ratios
| Caredx Inc (CDNA) | Exelixis (EXEL) | Kymera Therapeutics (KYMR) | PTC Therapeutics (PTCT) | Viking Therapeutics (VKTX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
9.60 | 13.16 | 0.00 | 20.60 | -- |
|
Asset Turnover
|
0.67 | 0.82 | 0.07 | 0.25 | 0.00 |
|
Receivable days
|
51.56 | 43.48 | 8.82 | 35.90 | -- |
|
Inventory Days
|
68.47 | 96.17 | -- | 261.74 | -- |
|
Payable days
|
26.19 | 147.97 | -- | 159.73 | 26,721.72 |
|
Cash Conversion Cycle
|
93.85 | -8.32 | -- | 137.90 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
